Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
NCHC ACTION FUND via NCHC ACTION FUND
2017 · fourth_quarter · Q4
Prescription drug pricing S. 974 - CREATES Act S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 2051 - FAST Generics Act of 2017 Medicare Part D biosimilars
Prescription Drug Pricing Medicare Part D biosimilars
Source: Senate LDA
Prescription drug pricing S. 974 - CREATES Act S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 2051 - FAST Generics Act of 2017 Medicare Part D biosimilars
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 2051 - FAST Generics Act of 2017 Medicare Part D biosimilars
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: NCHC ACTION FUND · Firm: NCHC ACTION FUND
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: NCHC ACTION FUND · Firm: NCHC ACTION FUND
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: NCHC ACTION FUND · Firm: NCHC ACTION FUND
Prescription drug pricing S. 974 - CREATES Act S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 2051 - FAST Generics Act of 2017 Medicare Part D biosimilars
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: NCHC ACTION FUND · Firm: NCHC ACTION FUND
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: NCHC ACTION FUND · Firm: NCHC ACTION FUND
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: NCHC ACTION FUND · Firm: NCHC ACTION FUND
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 2051 - FAST Generics Act of 2017 Medicare Part D biosimilars
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: NCHC ACTION FUND · Firm: NCHC ACTION FUND
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: NCHC ACTION FUND · Firm: NCHC ACTION FUND
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: NCHC ACTION FUND · Firm: NCHC ACTION FUND
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: NCHC ACTION FUND · Firm: NCHC ACTION FUND
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: NCHC ACTION FUND · Firm: NCHC ACTION FUND
Prescription drug pricing S. 974 - CREATES Act S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 2051 - FAST Generics Act of 2017 Medicare Part D biosimilars
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: NCHC ACTION FUND · Firm: NCHC ACTION FUND
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 2051 - FAST Generics Act of 2017 Medicare Part D biosimilars
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: NCHC ACTION FUND · Firm: NCHC ACTION FUND
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 2051 - FAST Generics Act of 2017 Medicare Part D biosimilars
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: NCHC ACTION FUND · Firm: NCHC ACTION FUND
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: NCHC ACTION FUND · Firm: NCHC ACTION FUND
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: NCHC ACTION FUND · Firm: NCHC ACTION FUND
Prescription drug pricing S. 974 - CREATES Act S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 2051 - FAST Generics Act of 2017 Medicare Part D biosimilars
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: NCHC ACTION FUND · Firm: NCHC ACTION FUND
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
Client: NCHC ACTION FUND · Firm: NCHC ACTION FUND
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Issues related to transparency and competition in the prescription drug market; the FDA Appropriations Act; S. 3056, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2016; S. 3335 Fair Accountability and Innovative Research Drug Pricing (FAIR)Act of 2016
Issues related to transparency and competition in the prescription drug market; the FDA Appropriations Act; S. 3056, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2016; S. 3335 Fair Accountability and Innovative Research Drug Pricing (FAIR)Act of 2016
Issues related to transparency and competition in the prescription drug market; FDA appropriations; S. 3056 - CREATES Act, S. 3335 Fair Drug Pricing Act
Issues related to transparency and competition in the prescription drug market; FDA appropriations; S. 3056 - CREATES Act, S. 3335 Fair Drug Pricing Act
Fair Accountability and Innovative Research Drug Pricing Act of 2016
Client: NCHC ACTION FUND · Firm: NCHC ACTION FUND
Issues related to transparency and competition in the prescription drug market; the FDA Appropriations Act; S. 3056, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2016; S. 3335 Fair Accountability and Innovative Research Drug Pricing (FAIR)Act of 2016
Fair Accountability and Innovative Research Drug Pricing Act of 2016
Client: NCHC ACTION FUND · Firm: NCHC ACTION FUND
Issues related to transparency and competition in the prescription drug market; the FDA Appropriations Act; S. 3056, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2016; S. 3335 Fair Accountability and Innovative Research Drug Pricing (FAIR)Act of 2016
Fair Accountability and Innovative Research Drug Pricing Act of 2016
Client: NCHC ACTION FUND · Firm: NCHC ACTION FUND
Issues related to transparency and competition in the prescription drug market; FDA appropriations; S. 3056 - CREATES Act, S. 3335 Fair Drug Pricing Act
Fair Accountability and Innovative Research Drug Pricing Act of 2016
Client: NCHC ACTION FUND · Firm: NCHC ACTION FUND
Issues related to transparency and competition in the prescription drug market; FDA appropriations; S. 3056 - CREATES Act, S. 3335 Fair Drug Pricing Act
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 2051 - FAST Generics Act of 2017 Medicare Part D biosimilars
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NCHC ACTION FUND via NCHC ACTION FUND
2017 · third_quarter · Q3
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Prescription Drug Pricing
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NCHC ACTION FUND via NCHC ACTION FUND
2017 · second_quarter · Q2
Prescription Drug Pricing
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NCHC ACTION FUND via NCHC ACTION FUND
2017 · first_quarter · Q1
Prescription Drug Pricing; CREATES Act
Prescription Drug Pricing
Prescription Drug Pricing; CREATES Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NCHC ACTION FUND via NCHC ACTION FUND
2017 · first_quarter · Q1
Prescription Drug Pricing; CREATES Act
Prescription Drug Pricing; CREATES Act
Prescription Drug Pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NCHC ACTION FUND via NCHC ACTION FUND
2016 · fourth_quarter · Q4
Issues related to transparency and competition in the prescription drug market; the FDA Appropriations Act; S. 3056, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2016; S. 3335 Fair Accountability and Innovative Research Drug Pricing (FAIR)Act of 2016
Issues related to transparency and competition in the prescription drug market
Issues related to transparency and competition in the prescription drug market; the FDA Appropriations Act; S. 3056, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2016; S. 3335 Fair Accountability and Innovative Research Drug Pricing (FAIR)Act of 2016
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NCHC ACTION FUND via NCHC ACTION FUND
2016 · third_quarter · RA
Issues related to transparency, competition and value in the pharmaceutical market place
Issues related to transparency, competition and value in the pharmaceutical market place
Issues related to transparency, competition and value in the pharmaceutical market place
NCHC ACTION FUND via NCHC ACTION FUND
2016 · third_quarter · Q3
Issues related to transparency and competition in the prescription drug market; FDA appropriations; S. 3056 - CREATES Act, S. 3335 Fair Drug Pricing Act
Issues related to transparency and competition in the prescription drug market
Issues related to transparency and competition in the prescription drug market; FDA appropriations; S. 3056 - CREATES Act, S. 3335 Fair Drug Pricing Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NCHC ACTION FUND via NCHC ACTION FUND
2016 · third_quarter · RR
Issues related to transparency and competition in the prescription drug market
Issues related to transparency and competition in the prescription drug market
Issues related to transparency and competition in the prescription drug market
Issues related to transparency and competition in the prescription drug market